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Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and αconotoxin Vc1.1 via GABAB receptor activation
Abstract

Neuronal Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) calcium channels contribute to synaptic
transmission and are modulated through G protein-coupled receptor pathways. The analgesic α-conotoxin
Vc1.1 acts through γ-aminobutyric acid type B (GABAB) receptors (GABABRs) to inhibit Cav2.2 channels.
We investigated GABABR-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the
GABABR agonist baclofen of human Cav2.1 or Cav2.3 channels heterologously expressed in human
embryonic kidney cells. 50 µM baclofen inhibited Cav2.1 and Cav2.3 channel Ba2+ currents by ∼40%,
whereas c-Vc1.1 did not affect Cav2.1 but potently inhibited Cav2.3, with a half-maximal inhibitory
concentration of ∼300 pM. Depolarizing paired pulses revealed that ∼75% of the baclofen inhibition of Cav2.1
was voltage dependent and could be relieved by strong depolarization. In contrast, baclofen or Vc1.1
inhibition of Cav2.3 channels was solely mediated through voltage-independent pathways that could be
disrupted by pertussis toxin, guanosine 5′-[β-thio]diphosphate trilithium salt, or the GABABR antagonist
CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Cav2.3 by c-Vc1.1.
Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a
phosphorylated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Cav2.3
demonstrated that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Cav2.3 by c-Vc1.1 and
are involved in baclofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src
phosphorylation sites into human Cav2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1
inhibition of Cav2.3, which defines Cav2.3 channels as potential targets for analgesic α-conotoxins, is caused
by specific c-Src phosphorylation sites in the C terminus.
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Differential Cav2.1 and Cav2.3 channel inhibition by baclofen
and -conotoxin Vc1.1 via GABAB receptor activation
Géza Berecki,1 Jeffrey R. McArthur,1 Hartmut Cuny,1 Richard J. Clark,2 and David J. Adams1
1

Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia
School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia

Neuronal Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein–coupled receptor pathways. The analgesic -conotoxin Vc1.1 acts
through -aminobutyric acid type B (GABAB) receptors (GABABRs) to inhibit Cav2.2 channels. We investigated
GABABR-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABABR agonist baclofen of
human Cav2.1 or Cav2.3 channels heterologously expressed in human embryonic kidney cells. 50 µM baclofen inhibited Cav2.1 and Cav2.3 channel Ba2+ currents by 40%, whereas c-Vc1.1 did not affect Cav2.1 but potently inhibited Cav2.3, with a half-maximal inhibitory concentration of 300 pM. Depolarizing paired pulses revealed that
75% of the baclofen inhibition of Cav2.1 was voltage dependent and could be relieved by strong depolarization.
In contrast, baclofen or Vc1.1 inhibition of Cav2.3 channels was solely mediated through voltage-independent
pathways that could be disrupted by pertussis toxin, guanosine 5-[-thio]diphosphate trilithium salt, or the GABABR
antagonist CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Cav2.3 by c-Vc1.1.
Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a phosphorylated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Cav2.3 demonstrated
that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Cav2.3 by c-Vc1.1 and are involved in bac
lofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src phosphorylation sites
into human Cav2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1 inhibition of Cav2.3, which
defines Cav2.3 channels as potential targets for analgesic -conotoxins, is caused by specific c-Src phosphorylation
sites in the C terminus.
INTRODUCTION

Presynaptic voltage-gated Cav2.1 (P/Q-type), Cav2.2
(N-type), and Cav2.3 (R-type) voltage-gated calcium
channels (VGCCs) mediate nerve-evoked transmitter release. Their modulation by G protein–coupled receptors
(GPCRs) is a key factor in controlling neuronal excitability at central and peripheral synapses (Luebke et al.,
1993; Takahashi and Momiyama, 1993; Wu et al., 1998;
Gasparini et al., 2001). Multiple GPCR-mediated pathways converge on VGCCs, but Cav2.3 channels are less
susceptible to direct G protein  dimer modulation
than Cav2.1 or Cav2.2 (Shekter et al., 1997), a finding attributed to differences between the N terminus, domain I,
and the I–II intracellular linker of Cav2.3 and Cav2.2
channels (Stephens et al., 1998; Simen and Miller, 2000).
Nevertheless, carbachol, somatostatin, ATP, and adenosine inhibit exogenous Cav2.3 channels via endogenous receptors in human embryonic kidney (HEK) cells
Correspondence to Géza Berecki: geza.berecki@rmit.edu.au
J.R. McArthur’s present address is Dept. of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138.
Abbreviations used in this paper: DRG, dorsal root ganglion; GABA,
-aminobutyric acid; GABAB, GABA type B; GABABR, GABAB receptor;
GDP--S, guanosine 5-[-thio]diphosphate trilithium salt; GPCR, G
protein–coupled receptor; HEK, human embryonic kidney; HP, holding
potential; IBa, Ba2+ current; PTX, pertussis toxin; VD, voltage dependent;
VGCC, voltage-gated calcium channel; VI, voltage independent.

(Mehrke et al., 1997). Interestingly, carbachol, a muscarinic receptor agonist, stimulates or inhibits Cav2.3 currents by distinct signaling pathways in HEK cells (Bannister
et al., 2004), whereas the D2 dopamine receptor agonist
quinpirole (Page et al., 1998) and µ opioid receptor agonist DAMGO (Ottolia et al., 1998) inhibit Cav2.3 currents
in the Xenopus laevis oocyte system. Electrophysiological
data suggest that baclofen, a derivative of -aminobutyric
acid (GABA), inhibits R-type currents in the rat medial
nucleus (Wu et al., 1998) and locus coeruleus neurons
(Chieng and Bekkers, 1999).
VGCCs are associated with a wide range of pathologies, including pain, and the value of selectively targeting Cav2 channels for neuropathic pain treatment is
recognized (Altier et al., 2007; Pexton et al., 2011). We
have shown that -conotoxin Vc1.1, a small venom peptide from Conus victoriae, inhibits Cav2.2 channels via
GABA type B (GABAB) receptors (GABABRs) in rodent
dorsal root ganglion (DRG) neurons (Callaghan et al.,
2008; Callaghan and Adams, 2010) and the HEK expression system (Cuny et al., 2012). We also demonstrated
© 2014 Berecki et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication
date (see http://www.rupress.org/terms). After six months it is available under a Creative
Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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MATERIALS AND METHODS
Cell culture, clones, and transfections
HEK cells containing the SV40 large T antigen (HEK-293T) were
cultured at 37°C in 5% CO2 in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% (vol/vol) fetal bovine
serum (Invitrogen), 50 IU/ml penicillin, and 50 µg/ml streptomycin (Invitrogen). HEK-293 cells, stably expressing human
Cav2.1 (P/Q-type) channel 1A-2 splice variant (GenBank accession no. AF004883) or human Cav2.3c (R-type) channel 1E-3
splice variant (also called 1E-c; GenBank accession no. L29385),
were obtained from Merck and cultured according to procedures
described previously (Dai et al., 2008). Both cell lines express
human 2b-1 (GenBank accession no. M76559) and human 3a
(RefSeq accession no. NM_000725) auxiliary subunits, and the
human KCNJ4 (Kir2.3; GenBank accession no. U07364) channel
(Dai et al., 2008).
The human Cav2.1 (P/Q-type) channel, 1A, transcript variant
5 (RefSeq accession no. NM_001174080), cloned into pCMV plasmid, was provided by J. Striessnig (University of Innsbruck, Innsbruck, Austria). The human Cav2.3d (R-type) channel (fetal brain
1E-d, splice variant L27745) was provided by T. Schneider (University of Cologne, Cologne, Germany). The wild-type human Cav2.3c
(1E-c) channel (GenBank accession no. L29385) and mutant
Cav2.3c channels, 1E-c (Y1761F) and 1E-c (Y1765F), all cloned
into pCDNA3.1 vectors, were purchased from GenScript USA Inc.
The 1E-d splice variant is identical in amino acid sequence to 1E-c,
except for a 43–amino acid segment (insert III or exon 46) at the
C terminus of the 1E-d channel (Pereverzev et al., 2002). Human
2b-1 (RefSeq accession no. NM_000722) and human 3 channel
subunits, transcript variant 1 (RefSeq accession no. NM_000725),
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were purchased from OriGene Technologies, Inc. Site-directed
mutagenesis of the wild-type human Cav2.3d (1E-d) channel, resulting in 1E-d (Y1761F) or 1E-d (Y1765F), and site-directed mutagenesis of the wild-type human Cav2.1 (1A-5) channel, resulting in 1A-5
(L1852T) or 1A-5 (Q1852E), was performed with the QuikChange
II XL site-directed mutagenesis kit (Agilent Technologies), using
the following oligonucleotides: Cav2.3(Y1761F)-for, GCATGTGGCCGCATCCATTTCACTGAGATGTATGAAATG; Cav2.3(Y1761F)rev, CATTTCATACATCTCAGTGAAATGGATGCGGCCACATGC;
Cav2.3(Y1765F)-for, CATTACACTGAGATGTTTGAAATGCTGA
CTCTC; Cav2.3(Y1765F)-rev, GAGAGTCAGCATTTCAAACATC
TCAGTGTAATG; Cav2.1(L1852T)-for, GGCCGCATGCCTTACA
CGGACATGTATCAGATG; Cav2.1(L1852T)-rev, CATCTGATAC
ATGTCCGTGTAAGGCATGCGGCC; Cav2.1(Q1856E)-for, CTTAC
CTGGACATGTATGAGATGCTGAGACACATGTC; Cav2.1(Q1856E)rev, GACATGTGTCTCAGCATCTCATACATGTCCAGGTAAG.
For all primers, sense and antisense orientations are denoted as
“for” and “rev,” respectively. The names reflect the position of the
tyrosine to be mutated to a phenylalanine (Cav2.3), leucine to threonine (Cav2.1), or glutamine to glutamic acid (Cav2.1). All mutations were verified by automated DNA sequencing (Australian
Genome Research Facility).
HEK cells stably expressing Cav2.1 or Cav2.3c channels were
transiently cotransfected with plasmid cDNAs encoding human
GABABR1 (RefSeq accession no. NM_001470; 3 µg; OriGene
Technologies, Inc.), human GABABR2 (RefSeq accession no.
NM_005458; 3 µg; OriGene Technologies, Inc.), and enhanced
green fluorescent protein (eGFP) reporter gene construct (1 µg;
provided by J.W. Lynch, The University of Queensland, Brisbane,
Australia), using the calcium phosphate precipitation method
(Jordan et al., 1996). In separate experiments, pRC-CMV/Src encoding wild-type mouse c-Src or pRC-CMV/Src(K295R/Y527F)
double mutant mouse c-Src cDNA (provided by J. Ulrich, University of Iowa, Iowa City, IA) was also included in the above transfection
mixture. The K295R mutation in the ATP-binding site inactivates
the kinase, whereas the Y527F mutation abolishes intramolecular
interactions between the C-terminal tail and the SH2 domain (Gao
et al., 1997).
HEK-293T cells were transiently cotransfected with plasmid
cDNAs encoding human Cav2.1 channel transcript variant 5 (5 µg)
or wild-type or mutant human Cav2.3d channels (5 µg), human
2b-1 (5 µg) and human 3 (5 µg) auxiliary subunits, human
GABABR1 (3 µg), human GABABR2 (3 µg), and eGFP (1 µg). In a
separate series of experiments, HEK-293T cells were transiently
cotransfected with plasmid cDNAs encoding rabbit Cav2.1 channel
(RefSeq accession no. NM_001101693; 5 µg; provided by F. Meunier,
The University of Queensland, St. Lucia, Australia), rat 2-1 (5 µg;
provided by G.W. Zamponi, University of Calgary, Calgary, Canada)
and rat 3 (5 µg; provided by D. Lipscombe, Brown University,
Providence, RI) auxiliary subunits; human GABABR1 (3 µg) and
human GABABR2 (3 µg); and eGFP (1 µg). After transfection, cells
were plated on glass coverslips and incubated at 37°C in 5% CO2
for 6 h. Transfection medium was then replaced with culture medium, and cells were incubated at 30°C in 5% CO2.
Electrophysiology
Experiments were performed 3–5 d after transfection, using the
whole-cell patch-clamp technique. Currents through calcium
channels were recorded using barium (Ba2+) as the charge carrier. Cells expressing the proteins of interest were superfused with
a solution containing (mM): 110 NaCl, 10 BaCl2, 1 MgCl2, 5 CsCl,
30 TEA-Cl, 10 d-glucose, and 10 HEPES, pH 7.4 with TEA-OH, at
600 µl/min. Fire-polished borosilicate patch pipettes with tip
resistance values of 2–3 MΩ were filled with an intracellular solution containing (mM): 125 K-gluconate, 2 MgCl2, 5 EGTA, 5 NaCl,
4 MgATP, and 10 HEPES, pH 7.25 with CsOH. In a series of experiments, EGTA was included in the intracellular solution at a
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that Vc1.1 can be used as an analgesic in rat models of
neuropathic pain (Klimis et al., 2011). Cav2.3 channels
are also present in various nociceptors (Fang et al.,
2007, 2010) and contribute to pain behavior control by
spinal and supraspinal mechanisms (Saegusa et al.,
2000; Terashima et al., 2013). However, Cav2.3 modulation via GABABRs is incompletely characterized and has
not been reconstituted in any heterologous expression
system. Moreover, few drugs or toxins have specific Cav2.3
inhibitory effects (Schneider et al., 2013).
In this study, we hypothesized that -conotoxin Vc1.1
can modulate Cav2.1 and Cav2.3 channels via GABABR
activation. We designed experiments to examine the
mechanisms of VGCC Ba2+ current (IBa) inhibition by
baclofen and Vc1.1, with emphasis on voltage-dependent
(VD) and voltage-independent (VI) pathways, which
may be present in these cells. Our data show that Vc1.1
only inhibits Cav2.3 channels, despite baclofen efficiently
inhibiting both Cav2.1 and Cav2.3 channels. Using sitedirected mutagenesis in combination with functional
expression in HEK cells, we demonstrate that c-Src phosphorylation of specific tyrosine residues in the 1 subunit C terminus is sufficient to mediate Vc1.1 inhibition
of Cav2.3 channels. A preliminary report of these results,
in part, has been presented in abstract form (Berecki,
G., J.R. McArthur, and D.J. Adams. 2013. Australian
Neuroscience Society Inc. 33rd Annual Meeting. Abstr.
ORAL-03-03).
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Peptides, chemicals, and drugs
-Conotoxins Vc1.1, cyclized-Vc1.1 (c-Vc1.1), and PeIA were synthesized as described previously (Clark et al., 2006, 2010; Daly
et al., 2011). Synthetic Vc1.1 and PeIA are 16–amino acid residue
peptides with a characteristic helical region and two disulfide
bonds in a I–III, II–IV arrangement (Clark et al., 2006, 2010; Daly
et al., 2011). c-Vc1.1 exhibits better properties than the linear
Vc1.1 (also known as ACV1), including high chemical stability,
resistance to cleavage by proteases, and improved potency to inhibit N-type VGCCs (Clark et al., 2010). Most data on -conotoxin
effects on various Cav2 channels were obtained using c-Vc1.1, unless otherwise noted. GABA, baclofen, guanosine 5-[-thio]diphosphate trilithium salt (GDP--S), and pertussis toxin (PTX)
were purchased from Sigma-Aldrich. (2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl) phosphinic


acid hydrochloride (CGP55845) and pp60c-Src peptide (521–
533) were purchased from Tocris Bioscience.
c-Src phosphorylation site prediction
A publicly available catalog of phosphorylation motifs (http://
www.hprd.org/PhosphoMotif_finder; Amanchy et al., 2007) was
used to identify Src kinase substrate motifs within Cav2.1 and
Cav2.3 C-terminal regions corresponding to exon 37 (e37) of
Cav2.2 channel. This catalog does not use algorithms or computational strategies to predict phosphorylation but reports the presence of any literature-derived motifs.
Curve fitting and statistical analysis
Data analysis was performed in Clampfit 9.2 (Molecular Devices)
and Origin 9.0 (Microcal Software Inc.). The voltage dependence
of IBa activation was determined from I-V curves fitted to the following transform of a Boltzmann function: IBa = Gmax(V  Vrev)/
{1 + exp[(V  V0.5,act)/k]}, where Vrev is the extrapolated reversal potential, V is the membrane potential, IBa is the peak current elicited by the voltage pulse, Gmax is the maximum conductance,
V0.5,act is the voltage for half-maximal current activation, and k is
the slope factor (Favre et al., 1995). Current amplitudes obtained
in the presence of a compound (I) were normalized to current
amplitudes obtained under control conditions (I0). Concentration–response curves were obtained by plotting averaged relative
peak current amplitude (I/I0) against compound concentration
and fitting the Hill equation I = I0{[D]h/(IC50h + [D]h)} to resulting data, where I0 is the maximum peak current amplitude, [D] is
the concentration of the compound (drug), IC50 is the half-maximal
inhibitory concentration, and h is the Hill coefficient (slope).
Concentration–response curves are interpreted as functional responses by a ligand (baclofen or c-Vc1.1) against a change in ligand
concentration. Results shown in Fig. 2 (B and C) and Table 2 were
obtained by applying increasing concentrations of baclofen to the
extracellular solution. Because baclofen inhibition of Cav2.3 channels is irreversible, these experiments do not represent equilibrium
steady-state measurements (Christopoulos and Kenakin, 2002).
Data are mean ± SEM (n, number of experiments). Statistical
analyses were performed in Sigma Plot 11.0 (Systat Software, Inc.)
using Student’s t test for two groups or one-way ANOVA with Bonferroni post-hoc testing for multiple comparisons. When one-way
ANOVA failed, Kruskal–Wallis one-way ANOVA on ranks with
Tukey test for multiple comparisons was used. Differences were
considered statistically significant at P < 0.05.
Online supplemental material
Table S1 shows the parameters of the Boltzmann fits to I-V and
G-V curves in Cav2.1/GABABR cells in the presence of 0.5 or 10 mM
EGTA in the intracellular recording solution. Fig. S1 shows the
voltage dependence of baclofen inhibition of Cav2.3d channels in
the presence of 0.5 or 10 mM EGTA in the intracellular recording
solution. Whole-cell IBa was recorded from HEK cells transiently
coexpressing wild-type Cav2.3d or mutant Cav2.3d (Y1765F) channels and GABABRs. The online supplemental material is available
at http://www.jgp.org/cgi/content/full/jgp.201311104/DC1.

RESULTS
Differential inhibition of Cav2.3 and Cav2.1 channels
by -conotoxin Vc1.1 via G protein–coupled GABABRs

We investigated VGCC modulation by baclofen and
-conotoxin Vc1.1 in HEK cells stably expressing Cav2.1
(1A-2) or Cav2.3c (1E-c) channels and transiently expressing GABABRs (Cav2.1/GABABR cells or Cav2.3/
GABABR cells, respectively). Fig. 1 (A–C) shows typical
Berecki et al.
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concentration of 0.5 or 10 mM. GTP was not used in the intracellular solution to prevent IBa rundown caused by activation of signaling pathways when the whole-cell recording configuration
was established (Raingo et al., 2007). To minimize endogenous
currents, the osmolarity of solutions was adjusted with sucrose
(310-mOsm extracellular, slightly hypertonic with respect to the
295-mOsm intracellular solution).
Electrophysiological recordings were performed at room temperature (23–25°C) using Multiclamp 700B amplifiers (Molecular
Devices) controlled by Clampex 9.2/DigiData 1332 acquisition
systems. I-V relationships were recorded from a holding potential
(HP) of 80 mV using 100-ms depolarizations from 45 to +50 mV,
in 5-mV increments. Peak IBa was measured for each step and normalized to the cell’s maximal current. Normalized currents were
averaged across cells and plotted (mean ± SEM) as a function of
voltage. Test depolarizations to 10 mV (in cells coexpressing
Cav2.3 channels and GABABRs) or 15 mV (in cells coexpressing
Cav2.1 channels and GABABRs) of 150-ms duration were applied
at a frequency of 0.1 Hz from an HP of 80 mV, where IBa was
evaluated in the absence and presence of various compounds.
VD relief of the inhibition was assessed from an HP of 80 mV,
using a protocol with a 20-ms prepulse to +80 mV, a 5-ms interpulse to 80 mV, and a 40-ms test pulse to +10 mV. The percentage of IBa inhibited in the absence of a prepulse (PP IBa) or
presence of a +80-mV prepulse (+PP IBa) was determined according to [(I0PP  IPP)/I0PP] × 100, or [(I0+PP  I+PP)/I0+PP] × 100,
respectively, where I0+PP and I0PP represent current amplitudes
(controls) obtained with or without a prepulse in the absence of
a compound, respectively. I0PP was normalized to I0+PP. I+PP and
IPP represent current amplitudes obtained with or without a prepulse in the presence of a compound, respectively. The VI fraction was defined as (+PP IBa) × 100/(PP IBa), whereas the VD
fraction was calculated as (PP IBa)  VI.
Membrane currents were filtered at 3 kHz and sampled at
10 kHz. Leak and capacitive currents were subtracted using a P/4
pulse protocol. Peptides and various drugs were prepared from
stock solutions, diluted to appropriate final concentration, and
applied via perfusion in the bath solution. Data were stored digitally on a computer for further analysis. Current densities were
calculated by dividing the normalized current amplitude by the
cell capacitance measured at the start of each experiment.
In successive transfections, the magnitude of baclofen inhibition of IBa was routinely tested in HEK cells stably expressing
Cav2.1 or Cav2.3 channels and coexpressing GABABRs. In 5%
of all cells tested, IBa inhibition by baclofen was ≤25%. In such
cases, the results were not included in the analysis or the experiment was discontinued. When evaluating the Vc1.1 concentration
dependence of IBa inhibition, only a maximum of three different Vc1.1 concentrations per cell were tested because of the relatively long time needed to reach maximum inhibition with each
Vc1.1 concentration.
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GABABR and Cav2.3/GABABR cells and exhibited IC50
values similar to those obtained with baclofen (Table 2).
The c-Vc1.1 concentration dependence of IBa inhibition
in Cav2.3/GABABR cells (Fig. 2 F) resulted in IC50 and
Hill coefficient values of 290 ± 0.8 pM and 0.61 ± 0.1, respectively, and defined c-Vc1.1 as a potent Cav2.3 channel inhibitor (Table 2). Fig. 2 (A and C) and Table 1
summarize the average IBa inhibition by baclofen, GABA,
Vc1.1, c-Vc1.1, and PeIA in the absence and presence of
GABABRs. These results demonstrate that GABABR expression is needed for baclofen to inhibit Cav2.1 and
Cav2.3 channels, and for c-Vc1.1 to inhibit Cav2.3 channels. Moreover, the decreased response to baclofen
after c-Vc1.1’s effect is consistent with an overlap between the intracellular signaling mechanisms induced
by these two compounds (Figs. 1 B and 2 E).
Voltage dependence of GABABR-mediated inhibition
of Cav2.1 and Cav2.3 channels

Direct VGCC inhibition by G protein–dependent inhibitory pathways involves VD G binding to the poreforming subunit (Bean, 1989; Kasai and Aosaki, 1989;
Lipscombe et al., 1989). I-V relationships were recorded

Figure 1. Effects of -conotoxin c-Vc1.1 and baclofen
(bac) on stably expressed human Cav2.1 (1A-2) or human
Cav2.3c (1E-c) channels in the presence of transiently expressed human GABABR subunits R1 and R2 (GABABR).
(A and B) 50 µM baclofen inhibits Cav2.1 or Cav2.3c channel currents, whereas 200 nM c-Vc1.1 only inhibits Cav2.3c
currents. Bars indicate c-Vc1.1 or baclofen application.
IBa was evoked by 150-ms depolarizations to 10 mV (Cav2.3c)
or 15 mV (Cav2.1), applied every 10 s from an HP of 80 mV
(voltage inset). Peak current amplitudes were plotted as
a function of time. Representative IBa traces (right) are
shown at the times indicated by lowercase letters. Horizontal dotted line represents zero-current level. Note that
Cav2.1 current inhibition by baclofen is reversible on washout (A), whereas baclofen or c-Vc1.1 irreversibly inhibits
Cav2.3c currents (B). (C) 50 µM baclofen inhibits IBa in
Cav2.3/GABABR cells. Experimental procedures are similar to those in A or B.
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examples of depolarization-activated whole-cell IBa in
the absence or presence of 200 nM c-Vc1.1 or 50 µM
baclofen. In Cav2.1/GABABR cells, c-Vc1.1 did not modulate IBa but inhibited IBa in Cav2.3/GABABR cells. The
effect of c-Vc1.1 developed relatively slowly, reached
maximum inhibition 3–7 min after the response started,
and was irreversible (Fig. 1 B). The “linear” -conotoxin
Vc1.1 and -conotoxin PeIA also inhibited depolarization-activated IBa in Cav2.3/GABABR cells (Table 1).
These peptides have been shown to selectively inhibit
high voltage–activated N-type calcium channels by acting as G protein–coupled GABABR agonists in rat DRG
neurons (Callaghan et al., 2008; Daly et al., 2011).
Cav2.1/GABABR or Cav2.3/GABABR cells typically responded to baclofen, with relatively fast IBa inhibition
that was completely reversible or weakly reversible/irreversible, respectively (Fig. 1, A and C, and Table 1). In
most experiments, applying baclofen after c-Vc1.1 exposure further suppressed a small fraction (<10%) of
IBa in Cav2.3/GABABR cells. We determined the baclofen concentration dependence of IBa inhibition for
Cav2.1 and Cav2.3 channels (Fig. 2, B and D), resulting
in relationships described by the Hill equation (Table 2).
50 µM GABA also inhibited 40% of IBa in Cav2.1/
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T ab l e 1

Summary of IBa inhibition by baclofen, GABA, or -conotoxins in the presence or absence of GABABRs in HEK cells stably expressing human Cav2.1 or
Cav2.3c channels
Agonist

IBa inhibition (%)
Cav2.1 and GABABR

Cav2.1 alone

Cav2.3c and GABABR

Cav2.3c alone

Baclofen (50 µM)

39.9 ± 2.6 (17)

0 (5)

39.5 ± 4.3 (11)

0 (6)

GABA (50 µM)

38.4 ± 2.7 (7)

ND

39.3 ± 4.1 (9)

ND

Vc1.1 (200 nM)

0 (9)

ND

25.5 ± 4.2 (9)

ND

c-Vc1.1 (200 nM)

0 (10)

0 (6)

34.8 ± 2.9 (16)

0 (5)

PeIA (200 nM)

0 (3)

ND

27.0 ± 3.0 (3)

ND

Values represent mean ± SEM; n, number of experiments in parentheses; ND, not determined.

from 6.18 ± 0.3 mV (n = 8; control) to 7.40 ± 0.58 mV (n =
8; baclofen), but the difference was not statistically
significant (P = 0.083) in Cav2.1/GABABR cells. However, it should be noted that the inhibition of Cav2.1/
GABABR cells by baclofen (31.1 ± 2.6%) is slightly less
than the inhibition shown in Fig. 2 A and Table 1. This
is probably because of spontaneous IBa recovery from
inhibition that occurred even in the continuous presence of baclofen and could cause the underestimation
of the V0.5,act positive shift in these experiments. To reduce the contribution of recovery in this process, we

Figure 2. Stably expressed human Cav2.1 (1A-2) or human
Cav2.3c (1E-c) channel inhibition by baclofen (bac) and
-conotoxin Vc1.1 in the absence and presence of transiently
expressed human GABABR. (A and C) Bar graphs showing average IBa inhibition through Cav2.1 (A) or Cav2.3c
(C) channels by 50 µM baclofen, 200 nM Vc1.1, or 200 nM
c-Vc1.1. Numbers in parentheses indicate the number of
experiments. (E) Average IBa inhibited by 50 µM baclofen
applied before or after 200 nM c-Vc1.1; “before c-Vc1.1”
data are replotted from C. (B, D, and F) Concentrationdependent inhibition of IBa through Cav2.1 and Cav2.3c
channels by baclofen (B and D) and Cav2.3c channels by
c-Vc1.1 (F). See IC50 values in Table 2.
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in the absence and presence of baclofen in Cav2.1/
GABABR cells and Cav2.3/GABABR cells, or c-Vc1.1 in
Cav2.3/GABABR cells. The biophysical properties of ion
permeation through Cav2.1 and Cav2.3 channels stably
expressed in HEK cells have been characterized previously
(Dai et al., 2008). We evaluated any depolarizing shift in
the midpoint of activation (V0.5,act) of these channels,
which may indicate the presence of direct G modulation, by fitting I-V relationships to a modified Boltzmann
function (see Materials and methods; Fig. 3 A). Fits of
the normalized I-Vs revealed that V0.5,act shifted slightly
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T ab l e 2

Summary of half-maximal inhibitory concentration (IC50) and Hill slope values in HEK cells stably expressing human Cav2.1 or Cav2.3c channels and
transiently coexpressing GABABRs
Agonist

Cav2.1 and GABABR
IC50

Cav2.3c and GABABR

Hill slope

IC50

nM

Hill slope

nM

Baclofen

470 ± 34 (5)

0.73 ± 0.05

330 ± 72 (7)

0.75 ± 0.14

GABA

388 ± 17 (4)

0.76 ± 0.20

328 ± 102 (4)

0.75 ± 0.24

0.29 ± 0.08 (4–7)a

0.61 ± 0.14

c-Vc1.1

—

—

Values represent mean ± SEM; n, number of experiments in parentheses; see details of the fitting procedure in Materials and methods.
a
Each data point (Fig. 2 F) was obtained from four to seven individual experiments.

In Cav2.3/GABABR cells, the V0.5,act values were 3.44 ±
0.67 mV (n = 8) in the presence of baclofen and 0.44 ±
0.46 mV (n = 7) for c-Vc1.1 compared with 0.67 ± 0.24 mV
(n = 15; control). In these experiments, baclofen caused
a significant hyperpolarizing shift of V0.5,act (P < 0.001 vs.
control; one-way ANOVA). However, V0.5,act was not altered by c-Vc1.1 (P = 0.223).

Voltage dependence of Cav2.1 (1A-2)
and stably expressed Cav2.3c channel inhibition
via GABABR activation. (A) I-V relationships
in Cav2.1/GABABR cells (left) in the absence
(control) and presence of 50 µM baclofen, and
in Cav2.3/GABABR cells (right) in the absence
(control) or presence of 50 µM baclofen or 200 nM
c-Vc1.1. (Insets) Voltage protocol and representative normalized current traces (only 23 ms of
the 100-ms traces are shown). See Table S1 for
V0.5,act values. (B) Cav2.1 channel inhibition via
GABABR is VD, whereas that of Cav2.3c is VI.
Representative 15-mV depolarization-activated
inward IBa from Cav2.1/GABABR cells (top) in
the absence (control) or presence of 50 µM baclofen, without (PP) or after the application
of a depolarizing prepulse to +80 mV (+PP).
(Bottom) Representative 10-mV depolarizationactivated IBa from Cav2.3/GABABR cells in the
absence (control) or presence of 50 µM baclofen
or 200 nM c-Vc1.1. Dotted lines indicate zerocurrent level. The voltage protocol (top inset)
is described in Materials and methods. (Right)
Summary of IBa inhibition in the absence or presence of a prepulse. Data are mean ± SEM (paired
Student’s t test; *, P < 0.001 vs. control [PP] in
Cav2.1/GABABR cells). The number of experiments is in parentheses. VD, voltage dependent;
VI, voltage independent.
Figure 3.
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also investigated baclofen inhibition of IBa in Cav2.1/
GABABR cells, evoked by voltage ramps. To assess any
effect of divalent cation buffering on I-V relationships,
we included 0.5 or 10 mM EGTA in the intracellular
solution (Fig. 4 and Table S1). Voltage ramps in the absence and presence of baclofen resulted in V0.5,act values
similar to those obtained with voltage steps (Fig. 3 A).

Published March 31, 2014

c-Vc1.1 inhibition of Cav2.3 channels involves Gi/o
subunits and c-Src kinase

We evaluated the VI pathway leading to Cav2.3 channel
modulation by determining the fraction of IBa that could
be inhibited under various experimental conditions
(Fig. 5). In HEK cells stably expressing Cav2.3c channels (Cav2.3 cells) or Cav2.3 cells coexpressing GABABR
R2 subunits, neither 200 nM c-Vc1.1 nor 50 µM baclofen inhibits IBa, indicating that a fully functional
GABABR heterodimer is needed for proper signaling.
In Cav2.3/GABABR cells, the selective GABABR antagonist CGP55845 (1 µM) did not change IBa amplitude or
kinetics but strongly antagonized IBa inhibition by
c-Vc1.1 and reduced the effect of baclofen by 60%
compared with control. This confirmed that GABABR
needed to be activated for c-Vc1.1 and baclofen inhibitory effects to occur. When the hydrolysis-resistant GDP
analogue GDP--S (500 µM) was added to the intracellular recording solution, Vc1.1 and baclofen inhibitory effects were almost identically reduced. Overnight treatment

Effects of baclofen on stably expressed human Cav2.1 (1A-2) channels in the presence of transiently expressed human GABABRs
(Cav2.1/GABABR cells). (A) Baclofen-inhibition of IBa in the presence of 0.5 mM EGTA in the intracellular recording solution. 50 µM
baclofen reversibly inhibited IBa by 38.5 ± 3.9% (n = 5). (Left) Representative currents in the absence (control) and presence of bac
lofen, elicited by voltage ramps to +50 mV from an HP of 80 mV at 0.1 Hz. Dotted line represents zero-current level. (Middle) I-V
relationships in the absence and presence of baclofen. Current amplitudes were determined from voltage ramps at selected membrane
potentials (Vm). Solid lines are fits of the modified Boltzmann equation to normalized I-V relationships (see Materials and methods). (Right)
Voltage dependence of activation determined from G-V relationships. Relative conductance (G/Gmax) was calculated as IBa/(Vm  Vrev),
where Vrev is the reversal potential of the whole-cell current and plotted as a function of Vm. The normalized G-V relationships were
fitted with a Boltzmann function, G = Gmax/(1 + exp((V0.5,act  Vm)/k)), where V0.5,act is the potential at which the conductance is halfmaximally activated, and k is the slope factor. (B) Similar experimental procedures and data representation as shown in A, with 10 mM
EGTA in the intracellular recording solution. Baclofen reversibly inhibited IBa by 41.8 ± 4.7% (n = 6). See Table S1 for V0.5,act (voltage for
half-maximal current activation) and k (slope factor) values resulting from experiments shown in A and B.
Figure 4.
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We evaluated if baclofen inhibition of IBa in Cav2.1/
GABABR and Cav2.3/GABABR cells, and c-Vc1.1 inhibition of IBa in Cav2.3/GABABR cells, could be reversed by
strong depolarization. A +80-mV prepulse of 20-ms duration was applied before the test pulse to relieve any
VD component of G protein–mediated IBa inhibition
(Fig. 3 B). In both cells, shortening (10 ms) or prolonging (50 ms) the prepulse or interpulse (10 ms) did not
change IBa facilitation. Applying +120-mV prepulses only
added 5% facilitation in Cav2.1/GABABR cells, without
changing IBa relief with Cav2.3/GABABR cells (not depicted). The inhibitory effect of baclofen was associated
with a large (73 ± 4%) VD component in Cav2.1/GABABR
cells. In contrast, the effect of baclofen and Vc1.1 was
solely mediated by a VI pathway in Cav2.3/GABABR cells,
which clearly indicates that intracellular signaling does
not involve the classical G protein  dimer (G) binding to the pore-forming Cav2.3 channel subunit. Alternatively, G could bind with high affinity to the Cav2.3
channel in a VI manner.
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c-Vc1.1 and baclofen inhibit stably expressed Cav2.3c
calcium channels via G protein–coupled GABABRs. Neither compound inhibits IBa in the absence of GABABRs (see also Fig. 2 C)
or the absence of GABABR R1 subunits. 1 µM CGP55845 or 500 µM
GDP--S significantly reduces c-Vc1.1 and baclofen responses,
respectively. A 24-h pretreatment with 1 µg/ml PTX abolishes
the effect of c-Vc1.1 or baclofen. Data are mean ± SEM (oneway ANOVA; *, P < 0.001 vs. controls; Cav2.3/GABABR cells with
c-Vc1.1 or baclofen, respectively).
Figure 5.
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Tyrosines 1761 and 1765 are needed in the C terminus
for c-Src phosphorylation of Cav2.3 channels

Alternative splicing of Cav2.1, Cav2.2, and Cav2.3 genes
creates channels with distinct kinetic, pharmacological,
and modulatory properties (Bourinet et al., 1999; Bell
et al., 2004; Fang et al., 2007; Gray et al., 2007). It has
been reported that GPCR-mediated inhibition of the
nociceptor-specific Cav2.2[e37a] channel occurred via
VD and VI pathways. In HEK cells coexpressing GABABRs
and Cav2.2[e37a] channels, the baclofen-induced VI
component required a tyrosine (Y) residue in e37a to
be phosphorylated (Raingo et al., 2007).
Alignment of the Cav2.2 channel e37a and e37b regions with the corresponding e37 regions in human
Cav2.3c, Cav2.3d, and Cav2.1 (1A-2 or 1A-5), and rabbit
Cav2.1 channels, indicated a degree of structural conservation and the presence of tyrosine kinase consensus
sites (Fig. 7 A). We hypothesized that Y residues within
e37 at the proximal C terminus in Cav2.3 channels could
serve as substrates for phosphorylation by c-Src. Using a
publicly available catalog of phosphorylation motifs
(Amanchy et al., 2007), we identified putative c-Src kinase
phosphorylation sites in human Cav2.3 and rabbit Cav2.1,
but not in human Cav2.1 channels. In both human Cav2.3c
and Cav2.3d splice variants, the Y1761 and Y1675 (as numbered in GenBank accession no. L29385) are followed
by a threonine (T) or glutamic acid (E), respectively, as
are potential substrates for Src kinases. Remarkably, in
rabbit Cav2.1, the second Y residue followed by alanine
(A) also represents a Src motif described in the literature. In contrast, in the human Cav2.1 splice variants
1A-2 or 1A-5, the consensus Y1851 and Y1855 residues (as
numbered in RefSeq accession no. NM_001174080) lack
the neighboring amino acids that are needed to generate
known Src kinase substrates for phosphorylation (Amanchy
et al., 2007).
We conducted a structure–function study in the e37
region to identify the amino acid residues responsible
for the different sensitivity to c-Vc1.1. We also tested
their contribution to c-Src–mediated inhibition in HEK
cells transiently coexpressing GABABRs and transiently
expressing Cav2.3c or Cav2.3d splice variants, or human
or rabbit Cav2.1 channels. In patch-clamp experiments,
200 nM c-Vc1.1 inhibited human Cav2.3c and Cav2.3d
channels but did not affect human Cav2.1 (1A-5) (Fig. 7 B
and Table 3). This confirmed previous results in HEK
cells stably expressing Cav2.1 (1A-2) or Cav2.3c channels
in the presence of GABABRs (Figs. 1 and 2). In all experiments, 50 µM baclofen inhibited IBa. As predicted,
c-Vc1.1 also inhibited rabbit Cav2.1 channels, likely because of the presence of a putative c-Src phosphorylation site in the C terminus (Fig. 7 A).
Mutational analyses of the e37 region in the proximal
C termini of Cav2.3d or Cav2.3c demonstrated that the
Y1761F mutation completely abolished c-Vc1.1 inhibition of IBa, and the Y1765F mutation significantly reduced
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with 1 µg/ml PTX abolished c-Vc1.1 and baclofen inhibitory pathway(s) in Cav2.3/GABABR cells, suggesting that
the effects were mediated by Gi and/or Go proteins.
We previously showed that Vc1.1 inhibition of N-type
(Cav2.2) calcium channel currents can be blocked by a
phosphorylated synthetic pp60c-Src peptide (Callaghan
et al., 2008). This is probably a result of pp60c-Src binding to the SH2 domain of native c-Src protein in rat
DRG neurons. Therefore, we examined in more detail
the role of c-Src in the GABABR-mediated Cav2.1 or Cav2.3
channel inhibition by baclofen and c-Vc1.1 in the HEK
expression system (Fig. 6). We changed endogenous
HEK cell c-Src protein levels (Luttrell et al., 1999) by
including cDNAs of wild-type or mutant c-Src in our
expression system. In Cav2.1/GABABR cells, wild-type
c-Src protein overexpression or inclusion of the pp60cSrc peptide (50 µM) in the intracellular solution did
not affect baclofen inhibition of IBa. However, in Cav2.3/
GABABR cells, wild-type c-Src protein overexpression
dramatically increased the fraction of IBa inhibited by
c-Vc1.1 compared with control.
To further evaluate the effect of c-Src on Cav2.3/GABABR
cells, we overexpressed the K295R/Y527F c-Src double mutant, which is kinase inactive and functions as a
dominant-negative inhibitor of wild-type c-Src (Gao et al.,
1997). This construct reduced the effect of baclofen
compared with control and abolished c-Vc1.1’s inhibitory effect. The effect of K295R/Y527F c-Src was recapitulated with the pp60c-Src peptide, suggesting that
c-Src kinase activity is needed for VI inhibition of IBa by
c-Vc1.1 and baclofen (Fig. 6, A and B).
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DISCUSSION

The role of c-Src proteins in GABABR-mediated inhibition by c-Vc1.1 in HEK cells stably expressing human Cav2.3c
channels and GABABRs. (A) Time course of IBa through Cav2.3c
channels in the absence (control) and presence of 200 nM c-Vc1.1
or 50 µM baclofen. Bars indicate c-Vc1.1 or baclofen application.
Overexpression of wild-type c-Src protein increases the IBa fraction
inhibited by c-Vc1.1 (top). Overexpression of the double mutant
c-Src (K295R/Y527F) (middle) or pretreatment with the phosphorylated pp60c-Src peptide (50 µM) (bottom) abolishes the effect of c-Vc1.1 and reduces baclofen inhibition of IBa, respectively.
Representative current traces (right) are shown at the times indicated by lowercase letters (see Fig.1 B for control). IBa was evoked
by 150 ms, 0.1-Hz depolarizations to 10 mV, from an HP of 80 mV
(voltage inset). Peak current amplitudes were plotted as a function of time. Horizontal dotted lines indicate zero-current
levels. (B) Average data (±SEM) of IBa inhibition by c-Vc1.1 or
baclofen after pp60c-Src peptide (50 µM) pretreatment or wildtype c-Src coexpression in Cav2.1/GABABR or Cav2.3/GABABR
Figure 6.



In this study, we efficiently reconstituted human Cav2.1
and Cav2.3 channel modulation via human G protein–
coupled GABABRs. Baclofen, a GABABR agonist, inhibited IBa through both channels; however, -conotoxin
Vc1.1 only inhibited Cav2.3 channels. The effect of
Vc1.1 on Cav2.3 channels was completely VI and depended on the presence of specific c-Src phosphory
lation sites in the C terminus of the human 1E (Cav2.3).
These results define Cav2.3 channels as new targets for
analgesic -conotoxins.
Cav2 channels and chronic pain

It is well established that Cav2.2 channel inhibition by
antagonists or via GPCRs produces analgesia in animals and humans (Altier and Zamponi, 2004). GABABRmediated inhibition of Cav2.1 or Cav2.2 channels in
various neurons is well documented (Cox and Dunlap,
1992; Mintz and Bean, 1993; Lambert and Wilson,
1996) and has been shown to involve VD and VI second

cells, respectively, or double mutant c-Src (K295R/Y527F) coexpression in Cav2.3/GABABR cells (*, P < 0.001 vs. controls; oneway ANOVA). The number of experiments is in parentheses.
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the c-Vc1.1 inhibition (Fig. 7 B and Table 3). These results suggest that tyrosines 1761 and 1765 are critical for
mediating the effects of Vc1.1. Interestingly, these mutants, except the Cav2.3d (Y1765F), also reduced baclofen inhibition of IBa, which indicates that these Y
residues are also involved in baclofen signaling. We explored how mutation affects the VI component of inhibition, in the absence and presence of a depolarizing
prepulse, via baclofen inhibition of IBa through Cav2.3d
(Y1765F) channels. Experiments were performed with
either 0.5 or 10 mM EGTA in the intracellular recording solution to (a) identify any effects of intracellular
divalent cations on IBa facilitation (Zühlke et al., 1999),
and (b) rule out modulation by phospholipids (Delmas
et al., 2005) (Fig. S1). The results showed that the effect
of baclofen was solely mediated by a VI pathway, independent of a classical G binding.
We also generated human Cav2.1 (1A-5) (L1852T) and
Cav2.1 (1A-5) (Q1856E) channel mutants. Remarkably,
the introduced putative c-Src phosphorylation sites conveyed sensitivity to c-Vc1.1 in these channels. Baclofen
modulation was not affected by the Cav2.1 (L1852T) or
Cav2.1 (Q1856E) channel mutants (Fig. 7 B and Table 3).
Collectively, these data suggest that specific c-Src
phosphorylation sites in the C terminus are needed for
-conotoxin c-Vc1.1 inhibition of Cav2.3 and Cav2.1
channels. However, it remains possible that other residues are also involved in mediating baclofen’s inhibition of Cav2.3 channels.
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messenger pathways (Dolphin and Scott, 1986; DiverséPierluissi et al., 1997). We showed that a subset of conotoxins, including Vc1.1, also selectively inhibit
Cav2.2 channels by acting as G protein–coupled GABABR
agonists (Callaghan et al., 2008; Callaghan and Adams,
2010; Clark et al., 2010; Daly et al., 2011). This mechanism may help relieve nerve injury–induced neuropathic
pain (Klimis et al., 2011).
Studies involving pharmacological and genetic approaches have also established Cav2.3 channels as potential targets for drugs that treat chronic pain (Saegusa
et al., 2000; Qian et al., 2013). The anti-nociceptive role
of Cav2.3 channels was demonstrated in rat dorsal horn

neurons (Matthews et al., 2007), and their inhibition was
associated with high efficiency opioid therapy without
tolerance (Yokoyama et al., 2004). Cav2.3 channels are
ubiquitously expressed in the central and peripheral nervous systems, but their physiological roles and modulation is not well understood. They typically conduct a
small proportion of whole-cell Ca2+ current and are difficult to isolate in neurons (Schneider et al., 2013).
Baclofen and -conotoxin Vc1.1 differentially inhibit Cav2.1
and Cav2.3 channels

Our results demonstrate that baclofen or GABA inhibits
IBa to a similar extent in Cav2.1/GABABR and Cav2.3/
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Kinase-dependent phosphorylation of the intracellular proximal C terminus is needed for VI Cav2.3 channel inhibition by
c-Vc1.1. (A) Amino acid sequence alignments of e37 regions in splice variants of Cav2.2, Cav2.1, and Cav2.3 and mutant Cav2.1 and Cav2.3
genes. Y (red), followed by A, E, or T (orange), is shown as a possible substrate for c-Src phosphorylation. (Right) Proposed model for
c-Vc1.1–induced intracellular signaling leading to Cav2 channel inhibition. Asterisk indicates phosphorylation. (B) Average IBa inhibition in the presence of 200 nM c-Vc1.1 or 50 µM baclofen in HEK 293T cells transiently cotransfected with wild-type human Cav2.3d
(1E-d) and Cav2.3c (1E-c); Cav2.1 (1A-5); rabbit Cav2.1 channel subunits; human e37 mutants Cav2.3d (Y1761F), Cav2.3d (Y1765F),
Cav2.3c (Y1761F), Cav2.3c (Y1765F), Cav2.1 (1A-5) (L1852T), or Cav2.1 (1A-5) (Q1852E); auxiliary human Cav channel subunits 2b-1
and 3; and human GABABR subunits. Representative normalized IBa traces (current insets) of wild-type or mutant channels are shown
in the absence (control) or presence of 200 nM c-Vc1.1 or 50 µM baclofen (only 65 ms of the 150-ms current traces are plotted). IBa was
evoked by depolarizations to +10 mV (Cav2.3c) or 15 mV (Cav2.1), applied at 0.1 Hz from an HP of 80 mV. Dotted lines indicate zerocurrent levels. Bar graphs show mean ± SEM; n, number of experiments in parentheses. Labels a, b, and c denote statistically significant
differences between various mutants and control; NS, not significantly different from wild-type modulation. See Table 3 for statistical
evaluation of the data.
Figure 7.
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time course of IBa activation in the presence of baclofen
or c-Vc1.1 seemed unaffected. In these cells, c-Vc1.1 did
not affect the I-V relationship, but baclofen caused a
hyperpolarizing I-V shift, which suggests that there may
be an additional signaling mechanism. Our results show
that neither baclofen nor Vc1.1 elicits VD inhibition of
Cav2.3 channels via GABABRs. However, it has been
shown that the rat brain 1Elong splice variant could be
inhibited in a VD manner via D2 dopamine receptors
(Page et al., 1998). Our alignment of the human 1E-c or
1E-d and rat 1Elong splice variants (not depicted) indicate that the N-terminal sequence responsible for VD
inhibition of rat 1Elong variant is present in human 1E-c
and 1E-d. Therefore, future experiments should determine whether or not human Cav2.3 channels can be
inhibited via D2 receptors in a VD manner. VD modulation may depend on the type of GPCR and specific
signal transduction mechanism elicited by the GPCRspecific ligand.
The VI pathway leading to Cav2.3 channel inhibition
by baclofen or c-Vc1.1 could be disrupted by GDP--S,
a GDP analogue that keeps G permanently associated
with G. In all cases, PTX treatment abolished baclofen and c-Vc1.1 inhibition of IBa, indicating that
GABABRs couple with G proteins of the Gi/Go superfamily in cells expressing Cav2.3 channels (Fig. 5). Analysis of the VI pathway in Cav2.3/GABABR cells indicated
that signaling mechanisms that contribute to Cav2.3
channel inhibition, downstream of G protein subunits,
involve c-Src kinase activation. For example, wild-type
c-Src overexpression increased IBa inhibition, whereas the
dominant-negative double mutant c-Src or the pp60c-Src

T ab l e 3

Summary of IBa inhibition by baclofen and c-Vc1.1 in HEK 293T cells transiently coexpressing GABABRs and Cav2.1 or Cav2.3 channels
Cav2 channel

IBa inhibition (%)
c-Vc1.1 (200 nM)

Baclofen (50 µM)

Human Cav2.3d

23 ± 2.9 (8)

33.1 ± 1.8 (8)

Human Cav2.3d (Y1761F)

1.7 ± 0.3 (11)a

Human Cav2.3d (Y1765F)

11.3 ± 3.0 (10)b

Human Cav2.3c

28.0 ± 4.0 (10)

Human Cav2.3c (Y1761F)

0.37 ± 0.3 (8)a

Human Cav2.3c (Y1765F)

15.0 ± 3.2 (10)

Human Cav2.1

0 (8)

21.9 ± 1.8 (11)c
NS

28.9 ± 2.7 (10)

44.0 ± 3.0 (10)
14.6 ± 1.8 (8)c
b

28.9 ± 2.7 (10)d
44.4 ± 1.9 (9)

Human Cav2.1 (L1852T)

7.2 ± 1.4 (8)a

NS

50.6 ± 2.8 (8)

Human Cav2.1 (Q1856E)

6.6 ± 1.7 (8)b

NS

47.9 ± 3.0 (8)

Rabbit Cav2.1

#

20.0 ± 4.0 (7)

#

50.0 ± 5.0 (8)

Values represent mean ± SEM; n, number of experiments in parentheses. NS, not significantly different from wild-type modulation. One-way ANOVA with
Bonferroni post-hoc testing was used to test for statistically significant differences except when comparing the effect of c-Vc1.1 on wild-type or mutant
Cav2.1 (one-way ANOVA on ranks with Tukey test). Data marked with a hash symbol were not included in the statistical analysis. Note that the percentage
of inhibition with transiently expressed human Cav2.1 or Cav2.3c channels and transiently coexpressed GABABRs (above) is similar (within the statistical
margin of error) to that obtained with stably expressed human Cav2.1 or Cav2.3c channels in the presence of transiently coexpressed GABABRs (see Table 1).
a
P < 0.001 versus Cav2.3d with c-Vc1.1; P < 0.001 versus Cav2.3c with c-Vc1.1; and P = 0.002 versus human Cav2.1 with c-Vc1.1.
b
P = 0.003 versus Cav2.3d with c-Vc1.1; P = 0.008 versus Cav2.3c with c-Vc1.1; and P = 0.002 versus human Cav2.1 with c-Vc1.1.
c
P = 0.003 versus Cav2.3d with baclofen and P < 0.001 versus Cav2.3c with baclofen.
d
P < 0.001 versus Cav2.3c with baclofen.
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GABABR cells (Figs. 1 and 2). Throughout this study, we
used cells with similar electrophysiological characteristics and applied supra-maximal doses of baclofen (50 µM)
or c-Vc1.1 (200 nM) to make sure receptors were fully
activated and rule out the possibility that differences
were caused by cell variability.
In Cav2.1 channel–expressing cells, baclofen inhibition
was VD and could be relieved by a strong depolarizing
prepulse, reﬂecting transient dissociation of G protein
 subunits from the channel. The 20-ms prepulses and
5-ms interpulses were considered suitable for VD IBa
relief in Cav2.1 channels (Currie and Fox, 1997). Our
results on the voltage dependence of inhibition are
consistent with previous studies demonstrating baclofen
inhibition of Cav2.1 channels in adrenal chromaffin
cells and cerebellar Purkinje neurons (Mintz and Bean,
1993; Currie and Fox, 1997). We did not analyze the
time course of IBa activation in the presence of baclofen
or c-Vc1.1 in Cav2.1/GABABR or Cav2.3/GABABR cells.
However, in Cav2.1/GABABR cells, the time course of IBa
activation considerably slowed in the presence of baclofen when compared with control. This is a hallmark
of VD G binding to the 1A (Cav2.1) subunit (Fig. 3 B).
Interestingly, baclofen only caused a small and statistically insignificant shift of the I-V and G-V relationships
in Cav2.1/GABABR cells (Figs. 3 A and 4), which was
independent of the intracellular EGTA concentration.
Bourinet et al. (1996) also reported a similar slight positive shift of the µ opioid receptor–activated Cav2.1 channel I-V relationship, suggesting possible differences
between Cav2.1 and Cav2.2 channel–modulating membrane-delimited pathways. In Cav2.3/GABABR cells, the
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generally accepted that the amino acid sequence motif
around the tyrosine residue and three-dimensional
structure of the substrate proteins contribute to phosphorylation site specificity (Pawson et al., 2001). Our
structure–function studies confirmed that Y[A/E/T]
sequences are the likely c-Src phosphorylation substrates
and represent key switches for the molecular mechanisms involved. The lack of any effect of Vc1.1 on
human Cav2.1 channels agrees with the absence of a
c-Src motif in the e37 region and marginal VI component in cells expressing these channels. Interestingly,
c-Src motif Y[K] can also be identified in the Cav2.2[e37a]
channel, whereas such a motif is absent in Cav2.2[e37b].
Therefore, further studies are required to dissect the
effects of Vc1.1 on Cav2.2 channel splice variants. Our
results also suggest that the effects of baclofen on
Cav2.3 channels are, at least partially, controlled by c-Src
phosphorylation. Given that PTX completely abolishes
the inhibition by baclofen, an additional PTX-sensitive
pathway is probably also involved. Future studies should
be aimed at directly correlating Cav2.3 channel phosphorylation and dephosphorylation with inhibition and
(the absence of) recovery, respectively. Clearly, further
experiments are also needed to confirm that c-Src kinase directly phosphorylates Cav2.3 channels in vivo.
Therapeutic implications of Cav2.3 channel inhibition

Few studies have examined Cav2.3 (R-type) channel
modulation in neurons, where a combination of specific inhibitors is needed to completely block various
VGCCs while preserving the R-type calcium channel. In
thalamocortical neurons, R-type current modulation by
baclofen has been demonstrated and could be antagonized by CGP55845 (Guyon and Leresche, 1995). In rat
DRG neurons, we also observed R-type current inhibition by baclofen in the presence of specific L-, N- and
P/Q-type channel blockers (not depicted). However,
further studies are needed to demonstrate what contribution the R-type current component makes to the
whole-cell calcium conductance inhibited by Vc1.1 in
nociceptive neurons.
GABABR activation produces anti-nociceptive effects
in animal models of acute or chronic pain (Pan et al.,
2008; Bowery, 2010). Baclofen is mainly injected into
the spine to manage spasticity and neuropathic pain
and as an adjuvant analgesic for relieving cancer pain
(Zuniga et al., 2000; Yomiya et al., 2009). Its oral dose
must be carefully regulated because of possible side effects. Vc1.1 does not compete with baclofen for binding to receptors, but it targets the interface between
the GABABR ectodomains (see Adams and Berecki,
2013). Vc1.1 was tested in human clinical trials, but its
development was discontinued because of its lack of
potency at human 910 nicotinic acetylcholine receptor, which was proposed to be the molecular target
(McIntosh et al., 2009). However, with the emergence
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peptide abolished c-Vc1.1 inhibition of IBa (Fig. 6). This
suggested that Cav2.3 channels are a potential c-Src substrate. It has been demonstrated that certain protein
tyrosine kinases can be direct effectors of G proteins
(Bence et al., 1997), and GABA inhibition of Cav2.2
channels involves direct Go activation of Src kinase
(Diversé-Pierluissi et al., 1997). However, further studies are needed to elucidate whether baclofen or Vc1.1
inhibition of Cav2.3 channels involves direct Gi/Go activation of c-Src.
In Cav2.1 and Cav2.2 channels, intracellular N and
C termini and cytoplasmic loops connecting domains
I–IV have been shown to interact with other proteins
and are targeted by second messenger pathways, including phosphorylation by kinases (Zamponi and Currie,
2013). Many of these interaction or modulatory sites
can also be identified in Cav2.3 channels (Schneider
et al., 2013). Furthermore, alternative splicing, recognized as a mechanism for creating functional diversity
in VGCCs (Gray et al., 2007), results in a series of Cav2.3
splice variants (Williams et al., 1994) with similar biophysical properties (Pereverzev et al., 2002). Of these,
Cav2.3c represents the major neuronal type variant, which
is dominantly expressed in the adult central nervous
system (Schneider et al., 2013), whereas Cav2.3d, the
variant cloned from human fetal brain (Schneider et al.,
1994), shows minor in vivo expression in the adult brain
(Pereverzev et al., 2002). Interestingly, the endocrine
splice variant Cav2.3e was also identified in nociceptive
trigeminal ganglion and DRG neurons together with
Cav2.3a (Fang et al., 2007, 2010). Importantly, the e37
region containing the putative c-Src phosphorylation
sites can be identified in all Cav2.3 splice variants.
There is evidence of multiple Src interaction sites in
various VGCCs. For example, Src interacts with both the
II–III linker and C-terminal tail regions of the L-type Ca2+
channel 1c subunit (Dubuis et al., 2006). c-Src kinases also
appear to be pre-associated with N-type VGCCs, efficiently
modulating their function (Schiff et al., 2000). In addition, c-Src kinases have been implicated in the GABABRmediated inhibition of Cav2.2 channels by baclofen
(Raingo et al., 2007) and Vc1.1 (Callaghan et al., 2008).
To date, GABABR-mediated modulation of Cav2.3
channels has not been reconstituted in expression systems, and c-Src phosphorylation of Cav2.3 channels has
not been demonstrated. Conserved Y residues within
the e37 region can be identified across all Cav2 family
members and appear to be key substrates for phosphory
lation by various tyrosine kinases. Our analysis of the
e37 regions in Cav2.1 and Cav2.3 channels predicted Src
kinase motifs in human Cav2.3 channels. These motifs
were absent in human Cav2.1 (Fig. 7). Although phosphorylation site prediction can be error prone, it is a
useful tool to determine whether e37 regions contain
sequence contexts typical of c-Src motifs described
previously in the literature (Amanchy et al., 2007). It is
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of new -conotoxin–based pharmacological tools that
act on neuronal VGCCs via the GABABR, its development
is likely to resume. It remains to be established if analgesic -conotoxins can be used as specific Cav2.2[e37a]
and Cav2.3 channel inhibitors for the treatment of
chronic pain.
In conclusion, we identified a previously unrecognized mechanism of -conotoxin Vc1.1 and baclofen
inhibition of Cav2.3 channels that involves GABABRs.
We systematically examined the intracellular pathways
and elucidated the molecular details that determine
c-Src phosphorylation of the Cav2.1 and Cav2.3 channel
C termini. Although the physiological significance of
kinase-mediated Cav2.3 channel inhibition is unclear, it
may have long-term influence over Ca2+-dependent intracellular signaling, exocytosis, and/or gene transcription in neurons.
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